midazolam + quinine

Midazolam + quinine is a combination of two pharmaceutical agents, each with distinct mechanisms and clinical uses. Midazolam is a short-acting benzodiazepine that acts as a positive allosteric modulator at the GABA(A) receptor, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. This results in sedative, anxiolytic, muscle relaxant, anticonvulsant, hypnotic, and amnesic properties[1][6]. Quinine is an antimalarial alkaloid primarily used for the treatment of uncomplicated *Plasmodium falciparum* malaria. Its mechanism involves antagonism of Fe(II)-protoporphyrin IX in *Plasmodium falciparum* parasites and inhibition of intermediate conductance calcium-activated potassium channel protein 4 in humans[8]. The combination may be encountered clinically when both drugs are co-administered (e.g., for sedation during malaria treatment), but significant drug-drug interactions exist due to shared hepatic metabolism via CYP3A4; quinine inhibits CYP3A4 and can increase midazolam exposure and risk of adverse effects[2][3][5].

Other names

midazolamquinine sulfate